Zupo Antonella, Pansy Katrin, Gaksch Lukas, Waldhart Julia, Brunner Andrea, Strobl Johanna, Szmyra-Polomka Marta, Haingartner Sandra, Tomazic Peter V, Greinix Hildegard T, Uhl Barbara, Feichtinger Julia, Stary Georg, Haybaeck Johannes, Vagena Fotini Rosi, Zacharias Martin, Beham-Schmid Christine, Neumeister Peter, Prochazka Katharina Theresa, Deutsch Alexander J A
Division of Hematology Medical University of Graz Graz Austria.
Institute of Pathology Medical University of Innsbruck Innsbruck Austria.
EJHaem. 2025 Aug 28;6(5):e70131. doi: 10.1002/jha2.70131. eCollection 2025 Oct.
: Classical follicular lymphoma (FL) is a heterogeneous malignancy. Early progression within 24 months (POD24) is linked to poor outcomes. However, precise risk stratification remains unclear. We aimed to explore chemokine receptor (CR) expression profiles as potential markers of disease biology and outcome in FL. : We analyzed mRNA expression of , -, , and in 52 FL samples (13 POD24, 39 non-POD24) using RT-qPCR. Immunohistochemistry for CCR3, CCR7, CXCR3, CXCR4, and CXCR5 was performed. Reactive tonsils ( = 5) served as controls. : Compared to controls, FL samples showed lower , , , , , and but higher , , , and expression. Grade 3a FL correlated with reduced , , and , and increased . POD24 cases had elevated , , CCR7, , and but reduced . High , , and levels were linked to inferior survival. Cluster analysis revealed two CR-based subgroups; most POD24 cases clustered in the group with worse prognosis. : These findings suggest distinct chemokine receptor expression profiles contribute to FL progression. Our data highlight several CRs as candidate prognostic markers and potential therapeutic targets in the context of POD24, warranting further investigation in larger, prospective cohorts. : The authors have confirmed clinical trial registration is not needed for this submission.
经典滤泡性淋巴瘤(FL)是一种异质性恶性肿瘤。24个月内早期进展(POD24)与不良预后相关。然而,精确的风险分层仍不清楚。我们旨在探索趋化因子受体(CR)表达谱作为FL疾病生物学和预后的潜在标志物。
我们使用RT-qPCR分析了52例FL样本(13例POD24,39例非POD24)中CCR1、CCR2、CCR3和CCR5的mRNA表达。对CCR3、CCR7、CXCR3、CXCR4和CXCR5进行了免疫组织化学检测。反应性扁桃体(n = 5)作为对照。
与对照相比,FL样本显示CCR1、CCR2、CCR3、CCR5、CXCR3和CXCR5表达较低,但CCR7、CXCR4和CXCR5表达较高。3a级FL与CCR1、CCR2和CXCR3表达降低以及CCR7表达增加相关。POD24病例中CCR3、CXCR3、CCR7、CXCR4和CXCR5升高,但CCR1降低。CCR7、CXCR4和CXCR5水平高与较差的生存率相关。聚类分析揭示了两个基于CR的亚组;大多数POD24病例聚集在预后较差的组中。
这些发现表明不同的趋化因子受体表达谱有助于FL进展。我们的数据突出了几种CR作为POD24背景下的候选预后标志物和潜在治疗靶点,值得在更大的前瞻性队列中进一步研究。
作者已确认本提交不需要临床试验注册。